

**Contact:**

Lori Yang, Interim CEO
and CSO

Locations:

San Diego, CA
Athens, GA

Email:

lyang@lectenz.com
info@lectenz.com

Tel:

706-549-4484

Website:

<http://www.lectenz.com>



Company Profile

Industry Sector: Biotechnology, Biopharma

Company Overview: Lectenz[®] Bio is developing novel products to aid the discovery of glycan biomarkers, furthering their application in human health. The company has developed the Lectenz[®] and GlycoSense[™] platforms for the high-throughput and cost-effective characterization of the glycan profiles of biomolecules. These are key enablers for disease biomarker detection and the development and production of therapeutic biologics and biosimilars in a multibillion dollar market. The company has extensive IP built with over \$4M in funded R&D and as part of commercialization rebranded from Glycosensors and Diagnostics to Lectenz[®] Bio.

Target Market(s): Bioprocessing, biomanufacturing, chromatography, biomarker detection.

Target Customer(s): Biopharma, CMOs, CROs, and research institutions.



Key Value Drivers

Technology: The Lectenz[®] and GlycoSense[™] platforms support glycan identification and analysis for applications in disease biomarker detection and bioprocessing of biologics and biosimilars.

Competitive Advantage: The products offer a robust, cost-effective, and unique solution (patents pending) to current bottlenecks in glycan analysis and will simplify the workflow associated with glycoprofiling during biologics development, biomanufacturing, diagnostics, and R&D.

Plan & Strategy: The company has grown its R&D through a successful series of Federal grants and both Federal and private contracts, and is now entering commercialization. Two Lectenz[®] kits are in beta testing in-house as well as in commercial settings. Product launches for these Lectenz[®] are expected early in 2018. We are currently seeking strategic partnerships, to expand our glycan analysis products in the biopharmaceutical and R&D markets.



Management

Board of Directors:

Lori Yang, Ph.D., Interim CEO, CSO – Technological development, corporate partnerships, non-dilutive funding.

Robert J. Woods, Ph.D., President, Professor of Biochemistry at the University of Georgia – Commercialization strategies, research direction.

Kausar N. Samli, Ph.D. – Partnerships, investor relations.

Corporate Advisors & Consultants:

Couch White, LLP – Corporate law.

Gordon & Rees, LLP – IP Licensing.

Insperty – Professional employer organization services.

Jameson & Company, LLC – Specialized CPA firm.

Mueting, Raasch & Gebhardt, P.A. – IP prosecution.



Revenue/Product Pipeline

Product Pipeline:

1. Sialic Acid Lectenz[®] for the detection of terminal sialic acid relevant to manufacturing biologics and analysis of markers relevant to PSA and influenza. (2017)

2. N-Glycan Lectenz[®] for the detection and enrichment of N-glycoproteins relevant to glycomics and manufacturing biologics such as mAbs. (2017)

3. GlycoSense[™] glycoenzyme reaction monitoring kits for *in vitro* glycoengineering. (2018)

4. GlycoSense[™] bioprocess monitoring kits for near real-time qualitative glycan analysis of biologics during biomanufacturing for Quality Assurance. (2018)

Additional Revenue Sources:

1. Service for custom designed Lectenz[®] reagents and GlycoSense[™] kits.

2. Joint Product Development Partnerships.